The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bacil Pharma Ltd
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma Ltd, a non-promoter entity, has disclosed an off-market acquisition of 20,90,000 equity shares (19.00%) of Shree Krishna Infrastructure Ltd on October 15, 2025. This took Bacil Pharma's holding from 0% to 19% in a single transaction. The acquisition was carried out under Regulation 29(1) of the SEBI Takeover Regulations, which requires disclosure when an acquirer crosses the 5% threshold. The target company has a total equity share capital of 1,10,00,000 shares of Rs. 10 each, listed on BSE (Scrip Code: 542146). The filing was signed by Ms. Chaitali Kalpataru Shah, Director & CFO of Bacil Pharma Ltd.
A new non-promoter entity now holds a sizeable 19% stake in Shree Krishna Infrastructure, which could influence future board composition or corporate actions. Shareholders should monitor whether Bacil Pharma plans to acquire further shares, which could trigger an open offer obligation under SEBI Takeover Regulations if it crosses the 25% threshold.